Article

Separable cell cycle arrest and immune response elicited through pharmacological CDK4/6 and MEK inhibition in RASmut disease models

2024-03-26

Abstract excerpt

<title>Abstract</title> <p>The combination of CDK4/6 and MEK inhibition as a therapeutic strategy has shown promise in various cancer models, particularly those harboring RAS mutations. An initial high-throughput drug screen identified high synergy between the CDK4/6 inhibitor palbociclib and the MEK inhibitor trametinib when used in combination for soft tissue sarcomas. In RAS mutant models, palbociclib and tram...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 7aaf51f3-9d6f-5696-ad97-6815a7550259
DOI: 10.21203/rs.3.rs-4138843/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Separable cell cycle arrest and immune response elicited through pharmacological CDK4/6 and MEK inhibition in RASmut disease modelsDOI 10.21203/rs.3.rs-4138843/v1Read

Separable Cell Cycle Arrest and Immune Response Elicited through Pharmacological CDK4/6 and MEK Inhibition in RASmut Disease Models.Semantic proximity Read

MAPK Reliance via Acquired CDK4/6 Inhibitor Resistance in CancerSemantic proximity Read

Differential Regulation of Cancer Progression by CDK4/6 Plays a Central Role in DNA Replication and Repair PathwaysSemantic proximity Read

Targeting Distinct Cell Cycle Nodes Overcomes KRAS/RAS Inhibitor ResistanceSemantic proximity Read

Acquired resistance to CDK4/6 inhibition is associated with dysregulation of multiple pathways including cyclin D-CDK4/6-RB, EGFR/HER, AKT/mTOR and IFN signalingSemantic proximity Read

Transcriptional Antagonism by CDK8 Inhibition Improves Therapeutic Efficacy of MEK Inhibitors.Semantic proximity Read

Suppression of IFN-Induced Transcription Underlies IFN Defects Generated by Activated Ras/MEK in Human Cancer CellsSemantic proximity Read

Targeting RAS Mutant Colorectal Cancer with Dual Inhibition of MEK and CDK4/6.Semantic proximity Read

MEK Inhibition Remodels the Immune Landscape of Mutant KRAS Tumors to Overcome Resistance to PARP and Immune Checkpoint Inhibitors.Semantic proximity Read

Molecular Pathways: Targeting the Cyclin D–CDK4/6 Axis for Cancer TreatmentSemantic proximity Read

Concomitant MEK and Cyclin Gene Alterations: Implications for Response to Targeted Therapeutics.Semantic proximity Read

Mediator Kinase Inhibition Impedes Transcriptional Plasticity and Prevents Resistance to ERK/MAPK-Targeted Therapy in KRAS-Mutant CancersSemantic proximity Read